I am not overwhelmed but am encouraged by the news. Seeing stronger effects in patients treated in second period (placebo then DMX-200) vs vice-versa is consistent with a legacy effects in this crossover design (I.e the good effects of DMX-200 taking longer than expected to wash out). The risk-reward profile here, especially given potential REMAP-CAP upside with continued GWAS hits near CCR2, continues to look favorable to me. Of course I would have welcomed partnership news but this is a decent step.
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-4
-
- There are more pages in this discussion • 166 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.5¢ |
Change
-0.005(1.06%) |
Mkt cap ! $255.8M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 48.5¢ | 46.5¢ | $1.514M | 3.204M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 121059 | 46.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.5¢ | 106197 | 4 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |